ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACON ACLARION, INC

Pre-Mkt 04-27 08:37:16 EDT

3.30

+0.04

+1.23%

盘前3.20

-0.10-3.03%

08:15 EDT

High3.35	Low3.26	Vol103.22K
Open3.34	D1 Closing3.26	Amplitude2.76%
Mkt Cap7.53M	Tradable Cap7.53M	Total Shares2.28M
T/O341.75K	T/O Rate4.52%	Tradable Shares2.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACON","market":"US","secType":"STK","nameCN":"ACLARION, INC","latestPrice":3.3,"timestamp":1777060800000,"preClose":3.26,"halted":0,"volume":103222,"hourTrading":{"tag":"盘前","latestPrice":3.2,"preClose":3.3,"latestTime":"08:15 EDT","volume":1003,"amount":3269.7661586000004,"timestamp":1777292119721,"change":-0.1,"changeRate":-0.030303,"amplitude":0.022848},"delay":0,"changeRate":0.012269938650306761,"floatShares":2282300,"shares":2282371,"eps":-13.608688,"marketStatus":"Pre-Mkt","change":0.04,"latestTime":"04-27 08:37:16 EDT","open":3.34,"high":3.35,"low":3.26,"amount":341751.6916352,"amplitude":0.027607,"askPrice":3.89,"askSize":100,"bidPrice":3.13,"bidSize":111,"shortable":3,"etf":0,"ttmEps":-13.608688,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777296600000},"marketStatusCode":1,"adr":0,"listingDate":1650600000000,"exchange":"NASDAQ","adjPreClose":3.3,"preHourTrading":{"tag":"盘前","latestPrice":3.2,"preClose":3.3,"latestTime":"08:15 EDT","volume":1003,"amount":3269.7661586000004,"timestamp":1777292119721,"change":-0.1,"changeRate":-0.030303,"amplitude":0.022848},"postHourTrading":{"tag":"盘后","latestPrice":3.25,"preClose":3.3,"latestTime":"19:51 EDT","volume":414,"amount":1345.9806,"timestamp":1777074679064,"change":-0.05,"changeRate":-0.015152,"amplitude":0.015152},"volumeRatio":0.35897097053598725},"requestUrl":"/m/hq/s/ACON","defaultTab":"news","newsList":[{"id":"2629044419","title":"Aclarion announces $2.5M share repurchase program","url":"https://stock-news.laohu8.com/highlight/detail?id=2629044419","media":"TIPRANKS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629044419?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:10","pubTimestamp":1776863435,"startTime":"0","endTime":"0","summary":"Aclarion (ACON) announced that its board of directors has authorized a share repurchase program of up to $2.5M of the company’s outstanding common ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclarion-announces-2-5m-share-repurchase-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclarion-announces-2-5m-share-repurchase-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629041252","title":"Aclarion Inc - Repurchase Program Expected to Be Executed Over Next 12 Months - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2629041252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629041252?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:01","pubTimestamp":1776862905,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN41515W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629495010","title":"Aclarion launches USD 2.5 million share buyback program","url":"https://stock-news.laohu8.com/highlight/detail?id=2629495010","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629495010?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:33","pubTimestamp":1776861183,"startTime":"0","endTime":"0","summary":"Aclarion authorized share repurchase program of up to USD 2.5 million for outstanding common stock.Company expects to execute buyback over next 12 months.Repurchases to be funded with existing cash and cash equivalents.Cash and cash equivalents totaled about USD 19 million as of March 31, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL48k32f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","LU0314104364.USD","BK4112","SG9999014005.SGD","IE00BN0W2W23.USD","BK4585","LU2210149790.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","IE00BN0W2V16.EUR","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","SG9999014021.USD","ACON","LU2210150020.SGD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049354","title":"Aclarion Announces $2.5 Million Stock Repurchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049354","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629049354?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:30","pubTimestamp":1776861000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA9Q7SBL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","ACON","ACONW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627294556","title":"Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2627294556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627294556?lang=en_us&edition=fundamental","pubTime":"2026-04-16 18:47","pubTimestamp":1776336479,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nFWN40Y17T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627512294","title":"Aclarion secures U.S. patent for AI-based chronic low back pain assessment platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2627512294","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627512294?lang=en_us&edition=fundamental","pubTime":"2026-04-16 18:47","pubTimestamp":1776336450,"startTime":"0","endTime":"0","summary":"Aclarion secured U.S. Patent 12,601,803 covering machine learning-based training and prediction to evaluate pain using magnetic resonance spectroscopy data.Patent supports planned automation in future Nociscan workflows, targeting faster report generation and fewer manual quality reviews.IP portfolio expanded to 64 issued and pending patents worldwide, strengthening competitive positioning in chronic low back pain assessment.Clinical data cited up to 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL2BHTqK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4585","SG9999014013.SGD","BK4167","LU0314104364.USD","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","IE00BN0W2V16.EUR","ACON","SG9999014005.SGD","NDAQ","LU2095319765.USD","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625494690","title":"Aclarion signs commercial agreement to bring Nociscan to Weill Cornell Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2625494690","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625494690?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:04","pubTimestamp":1775649888,"startTime":"0","endTime":"0","summary":"Aclarion signed commercial agreement with Weill Cornell Medicine to bring Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center.Nociscan will be available to a subset of spine patients in IRB-approved prospective study of bone marrow aspirate stem cell concentrate for osteoarthritis and degenerative disc disease .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL20xRKM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014039.USD","BK4585","SG9999014021.USD","BK4167","IE00BKPKM429.USD","NDAQ","IE00B64PRP62.GBP","BK4588","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","LU2095319765.USD","LU0314104364.USD","ACON","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210149790.SGD","BK4112","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625844946","title":"Aclarion Announces Agreement With Weill Cornell Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2625844946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625844946?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:00","pubTimestamp":1775649603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nTUA5KYWPJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4167","ACON","ACONW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625794667","title":"Press Release: Aclarion Announces Agreement with Weill Cornell Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2625794667","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625794667?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:00","pubTimestamp":1775649600,"startTime":"0","endTime":"0","summary":"BROOMFIELD, Colo., April 08, 2026  -- Aclarion, Inc.,  , a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence  algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with Weill Cornell Medicine.The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center and the multidisciplinary spine team led by triple-board certified physician and Principal Investigator, Jaspal Ricky Singh, MD, who has earned a national reputation for innovation and excellence. The trial is entitled \"A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate  for Osteoarthritis and Degenerative Disc Disease,\" conducted under IRB Protocol No. 22-06024915.\"Our team takes a comprehensive approach to the treatment of spinal disorders. Our multidisciplinary approach to treat pain includes physical therapy and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMAC","BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624729664","title":"Aclarion announces annual shareholder meeting, releases proxy statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624729664","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624729664?lang=en_us&edition=fundamental","pubTime":"2026-04-04 05:03","pubTimestamp":1775250211,"startTime":"0","endTime":"0","summary":"Aclarion scheduled 2026 annual meeting for June 4 in Broomfield, Colorado.Shareholders will vote to elect seven directors for terms running to 2027 annual meeting.Investors will also vote on amendment to 2022 Equity Incentive Plan, increasing share reserve to 500,000 from 42,974.Plan amendment would also lift annual per-participant award cap to 250,000 shares from 52 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL4pl8wb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622021442","title":"Aclarion Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2622021442","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622021442?lang=en_us&edition=fundamental","pubTime":"2026-03-25 17:42","pubTimestamp":1774431720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 05:42 ET (09:42 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621064345","title":"Echo Lake Capital urges Aclarion shareholders to oust director David Neal after 99% stock decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2621064345","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621064345?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:01","pubTimestamp":1774353705,"startTime":"0","endTime":"0","summary":"Echo Lake Capital sent a letter to board member David K. Neal calling for his immediate resignation and alleging failures to act in shareholders’ best interests.The investor said the stock has declined 99% since the IPO and said Neal has received more than USD 240,000 in board compensation since 2021.The letter said Neal accepted a 20% pay increase in 2025 and currently owns two shares valued at USD 6.24.Echo Lake Capital also criticized recently adopted anti-takeover measures that it said make it harder to replace directors and limit how much stock a shareholder can buy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL6GBw68:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Echo Lake Capital urges Aclarion shareholders to oust director David Neal after 99% stock decline","news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620194225","title":"Aclarion board adopts one-year stockholder rights plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2620194225","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620194225?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:26","pubTimestamp":1773926762,"startTime":"0","endTime":"0","summary":"Aclarion’s board unanimously adopted a limited-duration stockholder rights plan that takes effect immediately and expires in one year.The board declared a dividend of one preferred stock purchase right for each common share and each Rights-Eligible Warrant outstanding at the close of business on March 30, 2026.Each right allows the holder to buy 1/1,000th of a share of Series D Junior Participating Preferred Stock for USD 14 per right, subject to adjustment.The rights become exercisable if an unapproved party acquires 10% or more beneficial ownership of common shares, with certain grandfathering provisions for existing holders at or above that level.The plan permits redemption at USD 0.001 per right and includes an exchange feature of one common share per right, and it is scheduled to expire on March 18, 2027 unless earlier redeemed, exchanged, or terminated in specified transactions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL9bhf6g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BN0W2W23.USD","LU2210150020.SGD","BK4588","SG9999014005.SGD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","BK4112","IE00B3QW5Z07.USD","ACON","BK4167","LU2210149790.SGD","SG9999014013.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4585","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620198225","title":"Aclarion Inc - Rights Plan Expires March 18, 2027 Unless Earlier Redeemed, Exchanged, or Terminated","url":"https://stock-news.laohu8.com/highlight/detail?id=2620198225","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620198225?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:25","pubTimestamp":1773926740,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA35TJ0K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACONW","BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620162225","title":"Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2620162225","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620162225?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:25","pubTimestamp":1773926740,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA35TJ0K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACON","BK4167","ACONW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620249539","title":"Aclarion’s CEO publishes shareholder letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2620249539","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620249539?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:11","pubTimestamp":1773915068,"startTime":"0","endTime":"0","summary":"Aclarion (ACON)published a shareholder letter from CEO Brent Ness providing an update on the company’s recent momentum and value-creating prioritie...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclarions-ceo-publishes-shareholder-letter-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclarions-ceo-publishes-shareholder-letter-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620469802","title":"Aclarion Inc. Announces Availability of CEO Shareholder Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2620469802","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620469802?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:00","pubTimestamp":1773914429,"startTime":"0","endTime":"0","summary":"Aclarion said it published a CEO shareholder letter and made the full letter available on its website at .The letter, signed by CEO Brent Ness, provides an update on adoption of the Nociscan platform, clinical evidence development, and reimbursement initiatives in the UK and the US.It also references the CLARITY clinical trial, including an initial readout expected in Q4 2026.The letter notes a cash runway into 2028.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL3qDBlq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","LU0314104364.USD","BK4112","SG9999014005.SGD","IE00BN0W2W23.USD","BK4585","LU2210149790.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","IE00BN0W2V16.EUR","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","SG9999014021.USD","ACON","LU2210150020.SGD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620245006","title":"Aclarion reports 114% year-over-year increase in Q4 2025 Nociscan scan volumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2620245006","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620245006?lang=en_us&edition=fundamental","pubTime":"2026-03-19 17:48","pubTimestamp":1773913712,"startTime":"0","endTime":"0","summary":"Nociscan scan volumes in Q4 2025 more than doubled, rising 114% year-over-year.In the U.K., three of the four largest private insurers provide reimbursement coverage for Nociscan, covering 5.2 million people out of 69 million.The company reported no outstanding debt and 2.88 million shares outstanding on a fully diluted basis.Aclarion said its cash runway extends into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief on March 19, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL7kT9B8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACON","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620267072","title":"Aclarion FY 2025 net loss was USD 7.23 million as sales and marketing expenses nearly doubled to USD 1.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620267072","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620267072?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:58","pubTimestamp":1773867531,"startTime":"0","endTime":"0","summary":"Aclarion published its annual report on Form 10-K for FY 2025. Revenue rose 65.6% to USD 75,730, driven primarily by growing Nociscan report volumes in the UK following local coverage decisions. Sales and marketing expense more than doubled to USD 1.9 million, reflecting higher post-clearance clinical services tied to the CLARITY Trial and increased product marketing consulting. Net loss was USD 7.23 million. The company said it had USD 12.04 million in cash and cash equivalents and restricted cash as of Dec. 31, 2025, and expects current cash to fund operations into the first quarter of 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclarion Inc. published the original content used to generate this news brief via EDGAR, the Elec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL78c0w8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4167","ACON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620428060","title":"Aclarion to Participate in 38th Annual ROTH Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2620428060","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620428060?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:02","pubTimestamp":1773741769,"startTime":"0","endTime":"0","summary":"Aclarion to Participate in 38th Annual ROTH Conference               Aclarion is scheduled to participate in the 38th Annual ROTH Conference on March 22-24, 2026, in Dana Point, California. The releas","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLbQyk48:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014039.USD","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD","IE00BN0W2T93.GBP","BK4588","ACON","BK4585","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","LU2095319765.USD","BK4167","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclarion.com","stockEarnings":[{"period":"1week","weight":-0.0265},{"period":"1month","weight":0.0217},{"period":"3month","weight":-0.1316},{"period":"6month","weight":-0.5629},{"period":"1year","weight":-0.5681},{"period":"ytd","weight":-0.2826}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.316115},{"month":2,"riseRate":0.25,"avgChangeRate":-0.352706},{"month":3,"riseRate":0.25,"avgChangeRate":-0.242097},{"month":4,"riseRate":0.25,"avgChangeRate":-0.128558},{"month":5,"riseRate":0.5,"avgChangeRate":0.044825},{"month":6,"riseRate":0.25,"avgChangeRate":-0.115199},{"month":7,"riseRate":0.5,"avgChangeRate":-0.021585},{"month":8,"riseRate":0.5,"avgChangeRate":-0.066272},{"month":9,"riseRate":0.25,"avgChangeRate":-0.18466},{"month":10,"riseRate":1,"avgChangeRate":0.110748},{"month":11,"riseRate":0,"avgChangeRate":-0.1724},{"month":12,"riseRate":0,"avgChangeRate":-0.242895}],"exchange":"NASDAQ","name":"ACLARION, INC","nameEN":"ACLARION, INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ACLARION, INC(ACON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ACLARION, INC,ACON,ACLARION, INC股票,ACLARION, INC股票老虎,ACLARION, INC股票老虎国际,ACLARION, INC行情,ACLARION, INC股票行情,ACLARION, INC股价,ACLARION, INC股市,ACLARION, INC股票价格,ACLARION, INC股票交易,ACLARION, INC股票购买,ACLARION, INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ACLARION, INC(ACON),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ACLARION, INC(ACON) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}